CBIO:NSD-Catalyst Biosciences Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.71

Change

0.00 (-0.04)%

Market Cap

USD 0.02B

Volume

0.22M

Avg Analyst Target

USD 13.33 (+1,778.20%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Catalyst Biosciences Inc (CBIO) Stock Analysis:
Based on the Catalyst Biosciences Inc stock forecasts from 3 analysts, the average analyst target price for Catalyst Biosciences Inc is USD 13.33 over the next 12 months. Catalyst Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Catalyst Biosciences Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Catalyst Biosciences Inc’s stock price was USD 0.71. Catalyst Biosciences Inc’s stock price has changed by -0.08% over the past week, -0.30% over the past month and -89.32% over the last year.

About

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result fro ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

USD17.76B N/A N/A

ETFs Containing CBIO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -22.33% 26% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.33% 26% F 13% F
Trailing 12 Months  
Capital Gain -89.32% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.32% 2% F 2% F
Trailing 5 Years  
Capital Gain -91.91% 16% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.91% 16% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain 30.88% 66% D 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.88% 66% D 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 137.58% 18% F 10% F
Risk Adjusted Return 22.45% 52% F 39% F
Market Capitalization 0.02B 6% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.30 65% D 90% A-
Price/Book Ratio 0.56 98% A+ 97% A+
Price / Cash Flow Ratio -0.45 11% F 55% F
EV/EBITDA 0.32 64% D 93% A
Management Effectiveness  
Return on Equity -111.78% 24% F 17% F
Return on Invested Capital -79.46% 27% F 10% F
Return on Assets -56.76% 9% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.20 95% A 92% A-
Short Percent 0.77% 90% A- 77% C+
Beta 1.82 21% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector